{"id":"eporon","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EPORON activates erythropoietin receptors on erythroid progenitor cells in the bone marrow, promoting proliferation and differentiation into mature red blood cells. This mechanism increases hemoglobin and hematocrit levels, effectively treating anemia associated with chronic kidney disease, cancer chemotherapy, or other conditions causing reduced red blood cell production.","oneSentence":"EPORON is an erythropoietin (EPO) receptor agonist that stimulates red blood cell production to treat anemia.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:13.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Chemotherapy-induced anemia"}]},"trialDetails":[{"nctId":"NCT02603406","phase":"PHASE2","title":"Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits","status":"COMPLETED","sponsor":"Ajou University School of Medicine","startDate":"2016-07-15","conditions":"Angiogenesis, Ischemic Stroke","enrollment":44},{"nctId":"NCT03521713","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-03-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":214},{"nctId":"NCT02580006","phase":"PHASE1","title":"To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers","status":"UNKNOWN","sponsor":"Dong-A ST Co., Ltd.","startDate":"2015-11","conditions":"Healthy","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erythropoietin Alpha","EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU)"],"phase":"phase_3","status":"active","brandName":"EPORON","genericName":"EPORON","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EPORON is an erythropoietin (EPO) receptor agonist that stimulates red blood cell production to treat anemia. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}